For investors in 2017, the "high-risk, high-reward" segment of the market was defined by a strong rebound in energy, explosive breakthroughs in biotechnology, and the rising dominance of high-growth technology. While the broader market saw a lack of volatility, with the S&P 500 rising roughly 20% and the Nasdaq nearly 30%, these specific sectors offered triple-digit gains for those willing to stomach higher volatility.
: Another biotech leader, Nektar returned 387% following positive news regarding its immuno-oncology and painkiller treatments. high risk stocks to buy 2017
The following stocks represented some of the most successful speculative plays for the year: For investors in 2017, the "high-risk, high-reward" segment